3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Rhabdomyosarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Multiple Endocrine Neoplasia Type 2a
1
Medulloblastoma
1
Lethal Congenital Contracture Syndrome 2
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
128
Carboplatin
127
Pemetrexed
107
Cisplatin
80
Paclitaxel
60
osimertinib
55
Nivolumab
53
Docetaxel
52
durvalumab
49
Specimen Handling
40
Magnetic Resonance Spectroscopy
36
Gemcitabine
36
Radiosurgery
29
atezolizumab
27
130-nm albumin-bound paclitaxel
27
Cetuximab
26
Radiotherapy
23
Ipilimumab
22
Drug Therapy
22
cemiplimab
20
Bevacizumab
20
amivantamab
18
Taxes
16
Ramucirumab
13
tislelizumab
12
alectinib
12
Radiation
12
Biopsy
12
lazertinib
11
Oxaliplatin
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
Vascular Endothelial Growth Factor A
×
90 days
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled